Amarin Corp Plc (AMRN)

[Biobillionair]

Patent '994 PHARMACEUTICAL COMPOSITION COMPRISING OMEGA-3 FATTY ACID AND HYDROXY-DERIVATIVE OF A STATIN AND METHODS OF USING SAME

Imagine a new statin, one with the best lipid, inflamation, and side effect profile ever. Then add 5 yrs of NCE and a patent covering you until 2030...how much is this worth?

Hydroxy atorvastatin is a never approved prodrug of Atorvastatin, it's not in the OB or is it covered by any patent. It's well studied as it is a metabolite of Atorvastatin. The metabolite by itself is not that potent, so it was never investigated as a primary statin, but combined with Icosapent Ethyl the combination is more powerful than any individual or other combination statin.

Amarin should see NOA within 2013 for '994.

Williams